MiR-22 as a metabolic silencer and liver tumor suppressor

With obesity rate consistently increasing, a strong relationship between obesity and fatty liver disease has been discovered. More than 90% of bariatric surgery patients also have non-alcoholic fatty liver diseases (NAFLDs). NAFLD and non-alcoholic steatohepatitis (NASH), which are the hepatic manif...

Full description

Saved in:
Bibliographic Details
Published in:Liver research 2020-06, Vol.4 (2), p.74-80
Main Authors: Wang, Lijun, Wang, Yu-Shiuan, Mugiyanto, Eko, Chang, Wei-Chiao, Wan, Yu-Jui Yvonne
Format: Article
Language:English
Subjects:
Cancer
Hepatitis
Liver
Metabolism
MicroRNA-22(miR-22)
Non-alcoholic steatohepatitis
Steatosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With obesity rate consistently increasing, a strong relationship between obesity and fatty liver disease has been discovered. More than 90% of bariatric surgery patients also have non-alcoholic fatty liver diseases (NAFLDs). NAFLD and non-alcoholic steatohepatitis (NASH), which are the hepatic manifestations of metabolic syndrome, can lead to liver carcinogenesis. Unfortunately, there is no effective medicine that can be used to treat NASH or liver cancer. Thus, it is critically important to understand the mechanism underlying the development of these diseases. Extensive evidence suggests that microRNA 22 (miR-22) can be a diagnostic marker for liver diseases as well as a treatment target. This review paper focuses on the roles of miR-22 in metabolism, steatosis, and liver carcinogenesis. Literature search is limited based on the publications included in the PubMed database in the recent 10 years.
ISSN:2542-5684
2096-2878
2542-5684
DOI:10.1016/j.livres.2020.06.001